Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension

• Published in: Survey of ophthalmology 2004-03, Vol.49 (2), p.S12-S18
• Main Authors: Cantor, Louis B., WuDunn, Darrell, Cortes, Arnold, Hoop, Joni, Knotts, Stephenie
• Format: Article
• Language: English
• Subjects: Amides; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - adverse effects; Antihypertensive Agents - therapeutic use; Bimatoprost; Cloprostenol - administration & dosage; Cloprostenol - adverse effects; Cloprostenol - analogs & derivatives; Cloprostenol - therapeutic use; Cross-Over Studies; Double-Blind Method; Drug Evaluation; Female; glaucoma; Glaucoma, Open-Angle - drug therapy; Humans; intraocular pressure; Intraocular Pressure - drug effects; Lipids - administration & dosage; Lipids - adverse effects; Lipids - therapeutic use; Male; Middle Aged; ocular hypertension; Ocular Hypertension - drug therapy; Ophthalmic Solutions; Pilot Projects; Prospective Studies; target pressures; Travoprost
• ISSN: 0039-6257; 1879-3304
• DOI: 10.1016/j.survophthal.2003.12.015

To evaluate the IOP-lowering efficacy of bimatoprost and travoprost for the treatment of glaucoma and ocular hypertension. Randomized, investigator-masked, parallel-group clinical trial. After completing a washout from all glaucoma medications, patients (n=26) were randomized to bimatoprost or travoprost for 6 months. Visits were at baseline, week 1, and months 1, 3, and 6. IOP was measured at 9 am at each visit and also at 1 and 4 pm at baseline and months 3 and 6. At the baseline visit, there were no significant between-group differences in IOP at 9 am, 1 pm, or 4 pm (P≥.776). After 6 months of therapy, both medications provided significant mean reductions from baseline IOP at every time point (P≤.007). Mean IOP reductions ranged from 7.4 mm Hg to 8.8 mm Hg (34% to 36%) with bimatoprost and from 4.6 mm Hg to 7.2 mm Hg (19% to 29%) with travoprost (P≥.057) after 6 months of medication. At the final study visit, more patients achieved low target pressures with bimatoprost than with travoprost at each time point. Both study medications were well tolerated and ocular redness was the most commonly reported adverse event in both treatment groups. Although both bimatoprost and travoprost effectively lowered IOP in patients with glaucoma or ocular hypertension, bimatoprost provided larger mean IOP reductions than travoprost. More patients achieved low target pressures with bimatoprost than with travoprost. The between-group differences were not statistically significant due to the small sample size. These findings are being further evaluated in an ongoing multicenter clinical trial.